Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK101 in Moderately to Severely Active Ulcerative Colitis
NCT06281704Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2020
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ebdarokimab in ulcerative colitis (UC) (7 arms), sponsored by Akeso, Inc. Primary endpoints: Adverse Events at Week 36, Elimination half-life at Week 36 and 6 more. Started Nov 2020; status: completed.
02
Drugs
ebdarokimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06281704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281704.